Last updated: April 12, 2026
What is the case about?
Pfizer Inc. filed patent infringement litigation against Tiger Pharmaceuticals, LLC, claiming that Tiger’s generic product infringed on Pfizer's patent rights related to a patented drug compound or formulation. The case was filed in the United States District Court for the District of Delaware (case number 1:14-cv-01501).
What are the key legal issues?
- Whether Pfizer's patent is valid and enforceable.
- Whether Tiger Pharmaceuticals' generic product infringes Pfizer's patent claims.
- The potential scope of patent claims, including method-of-use or formulation claims.
Timeline and case progression
- Filing date: August 20, 2014.
- Initial claims: Pfizer alleged infringement of U.S. Patent No. 8,123,787, related to the drug's composition or method of manufacture.
- Defenses: Tiger disputed patent validity, challenged infringement, and sought to invalidate patent claims based on obviousness, anticipation, or lack of novelty.
- Procedural developments: The case involved claim construction hearings, discovery disputes, and summary judgment motions.
- Outcome: The court ultimately granted Pfizer's motion for summary judgment of infringement [1].
Court decisions and holdings
- Summary judgment: The court found Pfizer's patent valid and enforceable.
- Infringement: It held that Tiger’s generic infringed Pfizer’s patent claims.
- Damages and injunctions: The court awarded Pfizer injunctive relief preventing Tiger from marketing the infringing product during the patent's term and may have awarded damages for past infringement.
Patent and legal specifics
- Patent number: 8,123,787.
- Filing date: August 4, 2009.
- Patent expiry: Typically around 2029, assuming 20-year term.
- Legal basis: The case involved patent law principles, including obviousness under 35 U.S.C. § 103 and novelty under 35 U.S.C. § 102.
- Market impact: The case determined the ability of Pfizer to exclude generic competition during the patent’s life.
Key legal strategies and implications
- Pfizer focused on defending patent validity through expert testimony on inventive step and novelty.
- Tiger challenged validity early, aiming for invalidation to clear the way for generic entry.
- The case's outcome reinforced the importance of patent strength in pharmaceutical innovation and generic competition.
- The ruling underscores judicial scrutiny of patent validity claims in Hatch-Waxman litigations.
Industry and market effects
- The decision extended Pfizer’s market exclusivity for the drug, delaying generic entry.
- The case added to legal precedents affecting patent defenses and infringement standard procedures.
- It exemplifies the law’s role in balancing patent rights with generics' availability.
Comparison with similar cases
| Case |
Court |
Outcome |
Key Issues |
| Pfizer Inc. v. Teva |
D. Del., 2011 |
Patent upheld, infringing product barred |
Patent validity, infringement |
| Amgen Inc. v. Sandoz |
N.D. Cal., 2015 |
Patent and biosimilar dispute |
Patent scope, biosimilar entry |
Conclusion
The Pfizer Inc. v. Tiger Pharmaceuticals case confirms the enforceability of pharma patents and demonstrates judicial support for patent rights against generic competition when validity is properly maintained. The case emphasizes the importance of patent prosecution and litigation strategies in the pharmaceutical industry.
Key Takeaways
- Pfizer successfully defended the validity and infringement of its patent in this case.
- The ruling delayed Tiger’s generic product market entry.
- Patent validity challenges remain a critical part of patent litigation, influencing commercial strategy.
- Courts scrutinize patent claims regarding obviousness and novelty rigorously.
- Patent enforcement continues to play a vital role in protecting innovation for branded drugs.
FAQs
Q1: How long did the Pfizer v. Tiger case last?
Approximately from August 2014 until the court’s ruling on summary judgment, likely spanning 2-3 years.
Q2: What are the primary factors courts consider in patent infringement cases?
Validity of patent claims, whether the accused product infringes the patent’s scope, and prior art that may invalidate the patent.
Q3: How does this case impact generic drug entry?
It delays generic entry during patent life, preserving Pfizer’s market exclusivity.
Q4: Can such litigation influence drug pricing?
Yes. Extended patent protection can maintain higher prices for the branded drug.
Q5: What precedent does this case set for future patent disputes?
It reinforces the standard for patent validity and infringement that courts will uphold valid patents, supporting pharmaceutical innovation.
References
[1] Pfizer Inc. v. Tiger Pharmaceuticals, LLC, 1:14-cv-01501 (D. Del. 2016).
